What is the recommended treatment for a patient with severe pulmonary hypertension classified as World Health Organization groups I to III?

Treatment for Severe Pulmonary Hypertension WHO Groups 1-3

For WHO Group 1 (pulmonary arterial hypertension), initiate combination therapy with an endothelin receptor antagonist plus a phosphodiesterase-5 inhibitor or soluble guanylate cyclase stimulator, escalating to triple therapy including a prostacyclin pathway agent if inadequate response; for WHO Groups 2 and 3, PAH-specific therapies are NOT recommended as they lack proven benefit and may cause harm. 1, 2

WHO Group 1 (Pulmonary Arterial Hypertension) - Aggressive Treatment Indicated

Initial Risk Stratification and Vasoreactivity Testing

Before initiating therapy, perform vasoreactivity testing ONLY in patients with idiopathic PAH, heritable PAH, or drug-induced PAH 1. Use inhaled nitric oxide or IV epoprostenol during right heart catheterization. A positive response requires:

• Mean PAP reduction ≥10 mmHg
• Absolute mean PAP ≤40 mmHg
• Increased or unchanged cardiac output 1

Only 10-15% of patients respond positively. These rare responders can be treated with high-dose calcium channel blockers (amlodipine, diltiazem, or nifedipine). Do NOT perform vasoreactivity testing in other PAH subtypes or WHO Groups 2-5 1.

Pharmacologic Treatment Algorithm for Non-Responders (Majority of Patients)

For treatment-naive patients with severe PAH:

1. Initial therapy - Start with double combination therapy 2, 3:

   • Endothelin receptor antagonist (ambrisentan, bosentan, or macitentan) PLUS
   • Phosphodiesterase-5 inhibitor (sildenafil or tadalafil) OR soluble guanylate cyclase stimulator (riociguat)

2. Escalation timeline - Reassess at 3-6 months 3:

   • If inadequate response (persistent WHO functional class III-IV, worsening 6-minute walk distance, elevated NT-proBNP), escalate to triple therapy
   • Add prostacyclin pathway agent: IV epoprostenol (preferred for FC IV), subcutaneous/IV treprostinil, inhaled iloprost, or oral selexipag 2, 4

3. For WHO functional class IV at presentation - Consider starting IV epoprostenol-based triple therapy immediately rather than sequential escalation 4. Data show that 57.7% of FC IV patients who died had received IV prostacyclin, but many were undertreated 4.

Critical Pitfall to Avoid

Do NOT leave patients on monotherapy if they remain symptomatic. Real-world data from EXPOSURE show that 38% of patients on monotherapy required escalation to double therapy within a median of 3.4 months 3. Delayed escalation worsens outcomes. The evidence strongly favors upfront combination therapy over sequential monotherapy 2, 3.

WHO Group 2 (PH Due to Left Heart Disease)

PAH-specific therapies are contraindicated 1. These medications have not demonstrated benefit and may worsen pulmonary edema and left ventricular filling pressures. Treatment focuses on:

• Optimizing management of underlying left heart disease
• Diuretics for volume management
• Right heart catheterization is only indicated if considering transplantation 1

WHO Group 3 (PH Due to Lung Disease)

PAH-specific therapies are NOT recommended for routine use 1, 5. The evidence is compelling against their use:

• Meta-analysis of 5 RCTs in COPD-PH showed no significant improvement in 6-minute walk distance (42.7m improvement, 95% CI -1.0 to 86.3, not statistically significant) 5
• In ILD-PH, two RCTs showed no benefit (21.6m improvement, 95% CI -17.8 to 61.0) 5
• Severe PH (mean PAP ≥35 mmHg) with lung disease treated with vasodilators showed no improvement in functional class or 6MWD, with particularly poor outcomes in ILD patients 6

Treatment approach:

• Optimize management of underlying lung disease
• Supplemental oxygen to correct hypoxemia
• Consider referral for lung transplantation evaluation if severe PH develops 1
• Right heart catheterization indicated only for transplant evaluation 1

Exception Requiring Caution

If a patient has severe, out-of-proportion PH (mean PAP ≥35 mmHg with relatively preserved lung function), consider referral to a PH expert center to evaluate for possible misclassification or dual pathology. However, even in this scenario, outcomes with PAH therapies remain poor 6.

Supportive Care Across All Groups

Regardless of WHO group classification:

• Diuretics for volume overload
• Supplemental oxygen to maintain SpO2 >90%
• Influenza and pneumococcal vaccination 2
• Avoid pregnancy (high mortality risk)
• Anticoagulation consideration in WHO Group 1 only (controversial, not in Groups 2-3)

The fundamental principle: WHO Group 1 requires aggressive PAH-specific therapy with rapid escalation; WHO Groups 2 and 3 should NOT receive PAH-specific therapies outside of clinical trials or transplant bridge scenarios 1, 2, 5.